A new multi-parameter flow cytometric assay for monitoring lymphoma growth and spread in a pre-clinical murine model for human lymphoma

Cytometry Part A

Volumn 60, Issue 1, 2004, Pages 8-20

  Neeson, P ^a   Paterson, Yvonne ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

FACS; Idiotype; Lymphoma; Mouse

Indexed keywords

ANTIIDIOTYPIC ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CANCER GROWTH; CANCER MODEL; CELL KINETICS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 3042737572     PISSN: 15524922     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.a.20023     Document Type: Article

References (38)

1. Ruffini PA, Neelapu SS, Kwak LW, Biragyn A. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica 2002;87:989-1001.
2. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 1988;167:353-371.
3. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985;318:533-538.
4. 2 fragments against idiotypic determinants of its cell surface IgM. J Immunol 1983;131:1600-1603.
5. Eshhar Z, Blatt C, Bergman Y, Heimovich J. Induction of secretion of IgM from cells of the B cell line 38c-13 by somatic cell hybridization. J Immunol 1979;122:2430-2434.
6. Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky, R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol 1979;122:549-554.
7. Biragyn A, Surenhu M, Yang D, Ruffini PA, Haines BA, Klyushnenkova E, Oppenheim JJ, Kwak LW. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001;167:6644-6653.
8. Timmerman JM, Levy R. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J Immunol 2000;164:4797-4803.
9. McCormick AA, Kumagai MH, Hanley K, Turpen TH, Hakim I, Grill LK, Tuse D, Levy S, Levy R. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc Natl Acad Sci USA 1999;96:703-708.
10. Armstrong AC, Dermime S, Allinson CG, Bhattacharyya T, Mulryan K, Gonzalez KR, Stern PL, Hawkins RE. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J Immunol 2002;168:3983-3991.
11. Heyfets A, Haimovich J, Hollander N. Determination of idiotype-specific T cells in idiotye-vaccinated mice. Immunol Lett 2002;80:207-213.
12. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999;17:253-258.
13. Kwak LW, Pennington R, Boni L, Ochoa AC, Robb RJ, Popescu MC. Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. J Immunol 1998;160:3637-3641.
14. Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 1996;2:1038-41.
15. Hakim I, Levy S, Levy R. A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines. J Immunol 1996;157:5503-5511.
16. Dyke RJ, McBride H, George AJ, Hamblin TJ, Stevenson FK. Idiotypic vaccination against B-cell lymphoma leads to dormant tumour. Cell Immunol 1991;132:70-83.
17. Maloney DG, Kaminski MS, Burowski D, Haimovich J, Levy R. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 1985;4:191-209.
18. Vitetta ES, Tucker TF, Racila E, Huang YW, Marches R, Lane N, Scheuermann RH, Street NE, Watanabe T, Uhr JW. Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established. Blood 1997;89:4425-4436.
19. Bergman Y, Haimovich J. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol 1977;7:413-417.
20. Bergman Y, Haimovich J, Melchers F. An IgM-producing tumor with biochemical characteristics of a small B lymphocyte. Eur J Immunol 1977;7:574-579.
21. Carroll WL, Starnes CO, Levy R, Levy S. Alternative V kappa gene rearrangements in a murine B cell lymphoma. An explantation for idiotypic heterogeneity. J Exp Med 1988;168:1607-1620.
22. Starnes CO, Carroll WL, Campbell MJ, Houston LL, Apell G, Levy R. Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants. J Immunol 1988;141:333-339.
23. Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 1990;145:1029-1036.
24. Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993;362:755-758.
25. Chen TT, Tao MH, Levy R. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 1994;153:4775-4787.
26. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000;192:755-760.
27. Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI. NKT cells-conductors of tumor immunity? Curr Opin Immunol 2002;14:165-171.
28. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002;196:129-134.
29. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998.
30. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002;109:335-346.
31. de Stanchina E, Lowe SW. Tumour suppression: something for nothing? Nat Cell Biol 2002;4:E275-276.
32. Johnson A, Cavallin-Stahl E, Anderson H. Blood lymphocyte clonal excess in advanced non-Hodgkin's lymphoma. Relation to clinical data and prognosis. Ann Oncol 1993;4:393-398.
33. Weinberg DS, Pinkus GS, Ault KA. Cytofluorometric detection of B cell clonal excess: a new approach to the diagnosis of B cell lymphoma. Blood 1984;63:1080-1087.
34. Bartnes K, Hannestad K. Engagement of the B lymphocyte antigen receptor induces presentation of intrinsic immunoglobulin peptides on major histocompatibility complex class II molecules. Eur J Immunol 1997;27:1124-1130.
35. Sato K, Ochi A. Inhibition of B-cell receptor-antigen complex internalization by FcgammaRIIB1 signals. Immunol Lett 1998;61:135-143.
36. Maes J, Caspi Y, Rougeon F, Haimovich J, Goodhardt M. Secondary V(D)J rearrangements and B cell receptor-mediated down-regulation of recombination activating gene-2 expression in a murine B cell line. J Immunol 2000;165:703-709.
37. Weiner GJ, Kaminski MS. Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma. J Immunol 1989;142:343-351.
38. Hardy J, Edinger M, Bachmann MH, Negrin RS, Fathman CG, Contag CH. Bioluminescence imaging of lymphocyte trafficking in vivo. Exp Hematol 2001;29:1353-1360.